SCHEMBL3757381

SCHEMBL3757381

O=C(Nc1ccccc1-c1[c]nccc1)N1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
ABCC1 P33527 1/20 0.40
KMT2A Q03164 3/20 0.39
TSHR P16473 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
KDM4E B2RXH2 5/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 2/20 0.37
PKM P14618 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
SIGMAR1 Q99720 1/20 0.37
HSD17B10 Q99714 3/20 0.36
TRPV1 Q8NER1 2/20 0.36
ALOX12 P18054 1/20 0.36
MEN1 O00255 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3757735 0.80 RXFP1 (0.52) POLBKMT2ATSHRALDH1A1SIGMAR1
SCHEMBL5956417 0.77 POLB (0.61) POLBABCC1KMT2ACYP1A2CYP2D6
SCHEMBL3756488 0.76 FNTA (0.39) KMT2AKDM4EALDH1A1MAPK1SIGMAR1
SCHEMBL3754759 0.75 ALDH1A1 (0.47) POLBKMT2ATSHRCYP1A2CYP2D6
SCHEMBL3757382 0.75 POLB (0.52) POLBABCC1KMT2ACYP1A2CYP2D6
SCHEMBL3765034 0.74 HTR2C (0.35) POLBKMT2ATSHRALDH1A1SMN1; SMN2
SCHEMBL3759406 0.74 CDK4 (0.39) POLBALDH1A1SMN1; SMN2
SCHEMBL3760250 0.71 HTR7 (0.55) TSHRCYP1A2CYP2D6KDM4EALDH1A1
SCHEMBL669694 0.71 POLB (0.60) POLBABCC1KMT2AKDM4ESMN1; SMN2
SCHEMBL1221514 0.71 POLB (0.60) POLBABCC1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA POLB 2137/4885ABCC1 3355/4885KMT2A 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.